Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity

Romiplostim is recommended for the second- and third-line treatment of primary immune thrombocytopenia (ITP). We conducted a large, single-arm study (clinicaltrials.gov; NCT00508820) with broad entry